Medicine

A preexisting drug could buy time for snakebite treatment

Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?

The decline seen in some studies is normal, experts say. But scientists must wait to see whether infection confers long-term protection

Racial minorities and those with underlying health conditions may be at a greater risk from coronavirus infection, but have historically been less likely to be included in clinical trials

The assay looks for stomach, esophageal, colorectal, lung and liver malignancies

Drug manufacturers are racing to create a protective measure against coronavirus without destroying the patient’s immune system

Remote clinical trials and other changes could permanently alter pharmaceutical development

Participation rates were already low, but the pandemic threatens to drive them even lower

Rates of childhood immunization have fallen across the U.S., raising the risk of vaccine-preventable disease outbreaks​

What scientists know about the inner workings of the pathogen that has infected the world 

With little data on what works and what doesn’t, doctors trade tips and argue about risks

The results of a trial that found dexamethasone reduced the risk of death in extremely ill coronavirus patients have yet to be published, but some doctors are already embracing them